The ABCA1 agonist CS6253 shows favorable safety and pharmacokinetics in IND-enabling toxicology and Phase 1 human studies aimed at the indication of Alzheimer’s disease.

Cogpep (CS6253) - Artery Therap, University of California Berkeley

Jeffrey L. Cummings; Jan O. Johansson, MD, PhD; Daniel M Michaelson, PhD; Bengt Winblad, MD, PhD; Hussein N Yassine, MD; Henrik Zetterberg, MD, PhD

Jun 20, 2024